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LETTER TO THE EDITOR
Body weight and breast cancer
Sir - In their article, 'The relationship of body weight to
response to endocrine therapy, steroid hormone receptors
and survival of patients with advanced cancer of the breast',
Williams et al. (1988) address a topic of clinical importance.
In a retrospective analysis they found that body weight
influences size and oestrogen receptor status of breast
tumours, but not response to endocrine treatment or survival
of patients. They conclude, therefore, that body weight does
not meaningfully influence the course of breast carcinoma.
I disagree with this conclusion. Williams et al. have not
consistently taken into account the diversity of hormonal
sensitivity of breast tumours. The hormonal responsiveness
of breast tumours is heterogeneous from disease outset. Only
one-third of tumours are clinically oestrogen-sensitive; two
thirds are oestrogen-insensitive. While environmental hor-
mones such as oestrogens derived from gonads, adipose tis-
sue or exogeneous sources will not reverse the hormonal
insensitivity of tumours, they will influence the degree of
hormonal sensitivity of inherently hormone-dependent
tumours. Thus, an oestrogen-rich microenvironment will
progressively increase the oestrogen sensitivity of
hormone-dependent tumours by favouring the growth of
oestrogen-responsive subclones, but an oestrogen-rich
microenvironment will not reverse the oestrogen insensitivity
of tumours composed of receptor-deficient subclones or of
subclones with defective receptor-mediated mitogenic pathways.
Since both substrate availability and target responsiveness
are necessary for successful interaction, and since clinical
experience has shown that only those tumours that develop
after menopause are more often than not oestrogen-
dependent, it might have been more meaningful for the
authors to focus on this particular subgroup of patients. I do
not believe that competition between endogenous and
exogenous hormones for hormone-sensitive target tissues is
only of theoretical interest. Rather, I believe that dose escala-
tion of agonists, both to adjust for large endogenous sources
of antagonists and to adjust for tumours that as a conse-
quence contain a high proportion of hormone-sensitive sub-
clones, is as beneficial for patients with hormone-dependent
tumours as intensive chemotherapeutic regimens are thought
to be for large hormone-independent tumours. Thus, in our
own (unpublished) studies we found that body weight does
influence length of disease-free survival and response to
endocrine treatment in patients with hormone-responsive
tumours.
V. Hug
Dept of Medical Oncology,
University of Texas,
MD Anderson Cancer Center,
Houston, TX 77030, USA.
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Reply to the letter from V. Hug
Sir - In response to Dr Hug's letter we would first like to
correct the opening remarks. We did not find a significant
relationship between body weight and the oestrogen receptor
content of breast tumours. We did, however, report a
significant correlation between body weight and progesterone
receptor (PR) positivity (P = 0.01).
Dr Hug proceeds to develop the idea that an oestrogen-
rich microenvironment would promote the growth of oest-
rogen receptor (ER) positive cells within the tumour which
would render it progressively more oestrogen sensitive. This
hypothesis would predict that a higher proportion of ER
positive tumours would be found among heavier women
(given the insensitivity of standard assays to low amounts of
ER). There is, however, only one small series in the literature
to support this contention (de Waard et al., 1984) and our
own and one other study (Eberlein et al., 1985) found no
evidence of this effect. Furthermore there are reports of a
greater incidence of ER negative tumours among heavier
subjects, particularly among post-menopausal women
(Papatestas et al., 1980, 1986). We do not know of any
studies that have related the concentration of ER found in
ER positive tumours to body weight, particularly among
post-menopausal women which is clearly important to the
investigation of this hypothesis. It is not made clear whether
or not Dr Hug's (unpublished) studies provide support for
the theory of clonal selection. Among ER positive tumours
there was a significantly higher incidence of associated PR
positivity in heavier patients which, as PR is thought to be
induced by the action of oestrogen, provides confirmation
that high body weight is associated with increased levels of
biologically active oestrogen.
We are accused of not taking consistent account of the
diversity of hormonal sensitivity of breast tumours. However,
it is clearly stated that the time to progression from the start
of endocrine therapy and overall survival were not influenced
by body weight in any of the individual receptor categories
(i.e. ER +, ER -, PR +, PR -). Furthermore, there was no
difference in the time to progression and survival according
to body weight in each of the different categories of response
(i.e. complete, partial, no change and progressive disease),
which is probably a more accurate indicator of 'hormonal
sensitivity'.
Any effect of high body weight is more likely to be appar-
ent among post-menopausal women, as in premenopausal
subjects the contribution of fat-derived oestrogen to the total
body oestrogen production is likely to be insignificant in
relation to the ovarian output. In this study 74% of the
women were post-menopausal and in the multivariate
analysis no differences in clinical behaviour were observed
according to menopausal status as we clearly stated. We
would agree that post-menopausal women with ER positive
tumours are an important group but we found no evidence
that their response to tamoxifen and clinical behaviour is
influenced by body weight.
This study included 112 women with ER positive tumours,
most of whom were post-menopausal, which we believe is a